ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases

  1. Tripathy, D.
  2. Tolaney, S.M.
  3. Seidman, A.D.
  4. Anders, C.K.
  5. Ibrahim, N.
  6. Rugo, H.S.
  7. Twelves, C.
  8. Dieras, V.
  9. Müller, V.
  10. Tagliaferri, M.
  11. Hannah, A.L.
  12. Cortés, J.
Revista:
Future Oncology

ISSN: 1744-8301,  1479-6694

Any de publicació: 2019

Volum: 15

Número: 19

Pàgines: 2211-2225

Tipus: Article

DOI: 10.2217/FON-2019-0180 GOOGLE SCHOLAR lock_openAccés obert editor
Font de les dades: Scopus